| | | 宁波美诺华药业股份有限公司 关于"美诺转债"预计满足转股价格向下修正条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转换公司债券基本情况 （一）可转换公司债券发行上市概况 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公司公开发 行可转换公司债券的批复》（证监许可[2020]2377 号）核准，2021 年 1 月 14 日， 宁波美诺华药业股份有限公司（以下简称"公司"）公开发行 52,000 万元可转换 公司债券，共发行 520 万张，每张面值 100 元，期限 6 年。2021 年 2 月 4 日起， 上述可转换公司债券在上海证券交易所挂牌交易，转债简称"美诺转债"，转债 代码"113618"。 "美诺转债"存续的起止日期为 2021 年 1 月 14 日至 2027 年 1 月 13 日，转 股期起止日期为 2021 年 7 月 20 日至 2027 年 1 月 13 日，初始转股价格为 37.47 元/股。 （二）可转换公司债券转股价格历次调整情况 1、2021 年 12 ...

Core Points - The company has announced the second exercise period for its 2021 stock option and restricted stock incentive plan, allowing for the exercise of 738,491 shares from December 25, 2024, to November 24, 2025, with 278,530 shares exercised to date, representing 37.72% of the total available for this period [1][18][19] Decision-Making Process and Disclosure - On November 18, 2021, the company held its fourth board meeting, approving several proposals related to the stock option and restricted stock incentive plan, with independent directors expressing their agreement [1][2][3] - The company also held a temporary shareholders' meeting on December 6, 2021, where over two-thirds of the voting rights approved the same proposals [3] Adjustments and Approvals - On August 15, 2022, the company adjusted the number and price of the stock options and restricted stocks in the incentive plan [4] - The company completed the registration of 1,564,662 stock options on November 25, 2022 [6] Exercise and Trading Arrangements - The stock options will be exercised through a self-exercise method, with shares reaching the accounts of the incentive participants on the first trading day after the exercise date [18] - The total number of shares exercised as of November 24, 2025, is 278,530, with the total funds raised amounting to 6,328,201.60 yuan [19] Impact on Financial Reports - The exercise of these stock options is not expected to have a significant impact on the company's financial condition or operating results [19]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603538 证券简称：美诺华 公告编号：2025-112 重要内容提示： ● 本次行权股票数量：2021年股票期权与限制性股票激励计划预留授予股票期权第二个行权期可行权数 量为738,491股，行权期为2024年12月25日至2025年11月24日。截至2025年11月24日，累计行权278,530 股，占预留授予股票期权第二个行权期可行权总量的37.72%。 ● 本次行权股票上市流通时间：公司本次行权方式为自主行权，激励对象行权所得股票于行权日（T 日）后的第一个交易日（T+1日）到达股票账户，并于第二个交易日（T+2日）上市交易。 一、本次股票期权行权的决策程序及相关信息披露 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 关于2021年股票期权与限制性股票激励计划预留授予 第二个行权期自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 4、2022年8月15日，公司召开第四届董事会第十一次会议、第四届监事会第十次 ...

Core Viewpoint - Meihua announced the exercise of stock options under its 2021 stock option and restricted stock incentive plan, with a total of 738,491 shares available for exercise in the second exercise period [1] Summary by Sections Stock Options and Exercise Period - The number of stock options available for exercise in the second period is 738,491 shares, with the exercise period running from December 25, 2024, to November 24, 2025 [1] - As of November 24, 2025, a total of 278,530 shares have been exercised, representing 37.72% of the total options available for this exercise period [1] Listing and Trading Information - The company will implement a self-exercise method for the stock options, with shares obtained by the incentive recipients credited to their stock accounts on the first trading day after the exercise date (T+1) and available for trading on the second trading day (T+2) [1]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-112 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于 2021 年股票期权与限制性股票激励计划预留授予 第二个行权期自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次行权股票数量：2021 年股票期权与限制性股票激励计划预留授予股 票期权第二个行权期可行权数量为 738,491 股，行权期为 2024 年 12 月 25 日至 2025 年 11 月 24 日。截至 2025 年 11 月 24 日，累计行权 278,530 股，占预留授 予股票期权第二个行权期可行权总量的 37.72%。 本次行权股票上市流通时间：公司本次行权方式为自主行权，激励对象 行权所得股票于行权日（T 日）后的第一个交易日（T+1 日）到达股票账户，并 于第二个交易日（T+2 日）上市交易。 一、本次股票期权行权的决策程序及相关信息披露 1、 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The report emphasizes the importance of seizing opportunities following market corrections, particularly in anticipation of improvements in 2026. It notes that the pharmaceutical sector's fundamentals remain strong despite recent market fluctuations, and it is currently at a valuation bottom. The report suggests focusing on innovative drugs and companies with potential for operational improvements in 2025 [7][11]. Summary by Sections Industry Overview - The pharmaceutical sector consists of 498 listed companies with a total market capitalization of approximately 70,594.11 billion [2]. - The sector has experienced a decline of 6.88% recently, with various sub-sectors such as pharmaceutical commerce and biopharmaceuticals also facing downturns [11]. Market Dynamics - The report highlights a significant market correction, with the Shanghai Composite Index down by 3.77% and the pharmaceutical sector underperforming [11]. - It notes that the overall performance of the pharmaceutical sector has been positive since the beginning of the year, with a return of 13.69%, slightly outperforming the broader market [18]. Investment Opportunities - The report identifies key companies to watch, including: - CDMO leaders: WuXi AppTec, WuXi Biologics, and WuXi AppTec [11]. - Front-end CROs: Tigermed, ProPhase, and Zhaoyan New Drug [11]. - Medical devices: United Imaging Healthcare and HaiTai New Light [11]. - Biopharmaceuticals: I-Mab Biopharma and Hualan Biological Engineering [11]. - It also suggests focusing on companies with innovative drug pipelines and those that are transitioning from biotech to biopharma [11]. Company Performance - The report provides a list of recommended stocks, including: - WuXi AppTec (66.45), rated "Buy" - Three Life Pharmaceuticals (29.34), rated "Buy" - Tigermed (49.59), rated "Buy" - Xiansheng Pharmaceutical (12.85), rated "Buy" - Betta Pharmaceuticals (48.60), rated "Buy" [5][31]. Regulatory and Market Trends - The report discusses recent regulatory developments, including a call from the vaccine industry association to avoid low-cost bidding practices to stabilize profit margins for leading vaccine companies [11][12]. - It also notes significant acquisitions and advancements in drug development, such as Johnson & Johnson's acquisition of Halda Therapeutics for $30.5 billion [11].

Core Viewpoint - The company, Ningbo Menova Pharmaceutical Co., Ltd., is set to hold a performance briefing for the third quarter of 2025 on November 27, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The performance briefing will take place on November 27, 2025, from 13:00 to 14:45 [5]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live streaming and online interaction [5][4]. - Investors can submit questions for the briefing from November 20 to November 26, 2025, through the Roadshow Center website or via the company's email [6][2]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center online [4]. - The company will address commonly asked questions from investors during the briefing [3][6]. - The briefing will be led by the Chairman and General Manager, Yao Chengzhi, along with the Board Secretary and Financial Officer, Ying Gaofeng [5].

重要内容提示： 会议召开时间：2025 年 11 月 27 日 （星期四） 13:00-14:45 | | | 宁波美诺华药业股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 11 月 20 日（星期四）至 11 月 26 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过宁波美诺华药业股 份有限公司（以下简称"公司"）邮箱 nbmnh@menovopharm.com 进行提问。公司 将在说明会上对投资者普遍关注的问题进行回答。 宁波美诺华药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、 ...

Core Points - The company, Meinuo, announced on November 12 that it will not adjust the conversion price of its convertible bonds, known as "Meinuo Convertible Bonds" [1] - The period for triggering the price adjustment clause will restart from November 13, 2025, and the board will decide on any future adjustments if triggered [1] Summary by Sections - **Company Announcement** - Meinuo's board of directors approved the resolution not to lower the conversion price of the convertible bonds [1] - **Future Considerations** - The next period for triggering the conversion price adjustment clause will begin on November 13, 2025 [1] - The board will evaluate whether to exercise the right to adjust the conversion price if the clause is triggered again [1]

| | | 宁波美诺华药业股份有限公司 关于不向下修正"美诺转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 2、公司以 2022 年 6 月 7 日为股权登记日，实施 2021 年年度权益分派。每 股派发现金红利 0.19851 元（含税），以资本公积金向全体股东每股转增 0.397020 股，转增后公司总股本增加至 212,979,014 股。根据《募集说明书》约定，"美 诺转债"的转股价格由 37.23 元/股调整为 26.51 元/股。 截至 2025 年 11 月 12 日，宁波美诺华药业股份有限公司（以下简称"公 司"）股票已出现在任意连续三十个交易日中至少有十五个交易日的收盘价格低 于当期转股价格（25.68 元/股）90%，即低于 23.11 元/股（保留两位小数）的 情形，触发"美诺转债"转股价格向下修正条款。 2025 年 11 月 12 日，公司召开第五届董事会第十九次会议审议通过《关 于不向下修正可转换公司债券转股价格的议案》，公司董事会决定本次不向下修 正"美诺转债 ...